Literature DB >> 25459499

Comparison of resting and exercise echocardiographic parameters as indicators of outcomes in hypertrophic cardiomyopathy.

Patricia Reant1, Amelie Reynaud2, Xavier Pillois2, Marina Dijos2, Florence Arsac2, Cecile Touche2, Mathieu Landelle2, Caroline Rooryck2, Raymond Roudaut2, Stephane Lafitte2.   

Abstract

BACKGROUND: Both resting echocardiography and exercise echocardiography produce variables predictive of outcomes in patients with hypertrophic cardiomyopathy (HCM). The aim of the present study was to compare the respective value of resting and exercise echocardiographic parameters as indicators of clinical outcomes in patients with HCM.
METHODS: Resting and exercise echocardiography was performed prospectively in patients with HCM evaluated at the HCM Competence Center of Bordeaux and followed up every 6 months. A composite cardiac event was defined.
RESULTS: One hundred fifteen patients (mean age, 51.9 ± 15.2 years; 66% men) were evaluated by echocardiography and followed for a mean period of 19 ± 11 months. Eighteen patients (16%) reached the composite end point, including 10 progressions to New York Heart Association functional class III or IV. On rest echocardiography, in patients with cardiac events during follow-up, left atrial volume index was significantly more increased, as were lateral E/E' ratio and left ventricular outflow tract (LVOT) gradient, whereas mean global longitudinal strain (GLS) expressed in magnitude (14.0 ± 2.6% vs 17.0 ± 3.6%, P < .001) and peak velocities at the lateral annulus by Doppler tissue imaging were significantly reduced compared with patients without events. At peak exercise, patients who developed cardiac events were characterized by lower ejection fractions and greater LVOT gradients (76 ± 55 mm Hg vs 40 ± 40 mm Hg, P < .002). A Cox backward-entry selection model revealed that GLS ≤ 15% at rest and LVOT gradient ≥ 50 mm Hg at peak exercise were independently associated with an increased risk for poor outcomes in patients with HCM (hazard ratios, 3.8 [P = .017] and 3.3 [P = .028], respectively). On Kaplan-Meier survival analyses, peak exercise LVOT gradient evaluation showed additive value to predict outcomes, particularly in patients with rest GLS > 15% (log-rank P = .001) and despite a resting LVOT gradient ≥ 30 mm Hg (log-rank P = .001).
CONCLUSION: This study supports the value of resting GLS and of peak LVOT gradient, measured during exercise echocardiography, in identifying patients with HCM at increased risk for adverse events during follow-up.
Copyright © 2015 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Echocardiography; Exercise echocardiography; Hypertrophic cardiomyopathy; Myocardial strain; Prognosis

Mesh:

Year:  2014        PMID: 25459499     DOI: 10.1016/j.echo.2014.10.001

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  4 in total

1.  Exercise stress echocardiography in hypertrophic cardiomyopathy.

Authors:  Kengo Suzuki; Yoshihiro J Akashi
Journal:  J Echocardiogr       Date:  2017-05-13

2.  Characterization of hypertrophic cardiomyopathy according to global, regional, and multi-layer longitudinal strain analysis, and prediction of sudden cardiac death.

Authors:  Marie-Philippe Vergé; Hubert Cochet; Amélie Reynaud; Lucas Morlon; Jérôme Peyrou; Cécile Vincent; Caroline Rooryck; Philippe Ritter; Stéphane Lafitte; Patricia Réant
Journal:  Int J Cardiovasc Imaging       Date:  2018-02-27       Impact factor: 2.357

Review 3.  Cardiopulmonary Exercise Test in Patients with Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis.

Authors:  Adrián Bayonas-Ruiz; Francisca M Muñoz-Franco; Vicente Ferrer; Carlos Pérez-Caballero; María Sabater-Molina; María Teresa Tomé-Esteban; Bárbara Bonacasa
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

4.  Prognostic relevance of exercise testing in hypertrophic cardiomyopathy. A systematic review.

Authors:  Tiago Rodrigues; Sofia Cavaco Raposo; Dulce Brito; Luis R Lopes
Journal:  Int J Cardiol       Date:  2021-06-30       Impact factor: 4.039

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.